TSX: PMN
TORONTO, March 22, 2017 /CNW/ - ProMIS Neurosciences
("ProMIS" or the "Company"), a company focused on the discovery and development of precision treatments for neurodegenerative
diseases, today announced that it has appointed Daniel E. Geffken to the position of Chief
Financial Officer.
"We are pleased to welcome Daniel Geffken as his broad skill set and experience will contribute
significant value to the ProMIS team," said Eugene Williams, ProMIS Executive Chairman. "In
particular, Daniel's well–recognized expertise in building science-based companies and track record in strategic fundraising are
key capabilities that fit perfectly with the developing needs of ProMIS."
Daniel Geffken is a Founding Managing Director of Danforth Advisors, LLC and brings more than
25 years of experience in the life science industry to his work with ProMIS.
"I am delighted to join ProMIS, a rapidly developing company at the forefront of precision medicine treatments for
neurodegenerative diseases, particularly Alzheimer's disease and ALS," said Geffken. "I look forward to working with the
executive team to assist the company in achieving these important objectives."
About Daniel Geffken
Daniel Geffken is a Founding Managing Director of Danforth Advisors, LLC, a consulting firm
providing finance, operations and strategic support to life science companies. He brings more than 25 years of experience
in the life science industry to his work with ProMIS, ranging from start-ups to publicly traded companies with $1 billion+ market
capitalizations. He previously served as COO or CFO of four publicly traded and four privately held life science companies, in
addition to his consulting clients. Daniel has been chief financial officer of Homology, Inc, GenePeeks, Inc., Transkaryotic
Therapies, Inc., Cidara, Inc., Apellis, Inc. and Stealth BioTherapeutics, Inc. He has raised more than $1 billion in equity and debt securities for life science companies. Daniel holds a B.S. from The Wharton
School, University of Pennsylvania, and M.B.A. from Harvard Business
School.
About ProMIS Neurosciences, Inc.
The mission of ProMIS Neurosciences is to discover and develop precision medicine therapeutics for effective treatment of
neurodegenerative diseases, in particular Alzheimer's disease and ALS.
ProMIS Neurosciences' proprietary target discovery engine is based on the use of two, complementary techniques. The Company
applies its thermodynamic, computational discovery platforms—ProMIS™ and Collective Coordinates — to predict novel
targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision
medicine" approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for
Alzheimer's disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels
of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic
patents relating to misfolded SOD1 in ALS, and currently has three preclinical monoclonal antibody therapeutics against this
target.
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information
release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and
other factors that may cause actual results, performance or achievements to be materially different from those implied by
statements herein, and therefore these statements should not be read as guarantees of future performance or results. All
forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently
available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties
identified by the Company in its public securities filings, actual events may differ materially from current expectations. The
Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
For further information please consult the Company's website at: www.promisneurosciences.com
Follow us on Twitter
Like us on LinkedIn
SOURCE ProMIS Neurosciences Inc.
To view the original version on PR Newswire, visit: http://www.newswire.ca/en/releases/archive/March2017/22/c5954.html